Posted in | Nanomedicine | Nanobusiness

NanoViricides CEO to Serve as Panelist at 2nd Annual Livingston Healthcare Summit

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the Company's CEO, Eugene Seymour, MD, MPH has been invited as a panelist at the 2nd Annual Livingston Healthcare Summit on September 24th, 2009 in New York City.

Dr. Seymour will join other industry panelists in the “Drug Discovery and Development” session to discuss early to mid-stage financing and pharmaceutical alliance challenges and trends. The panelists and participants include pharmaceutical and biotech decision makers and executives, investors, government and regulatory agency representatives from a number of countries.

This is a unique, by invitation conference, designed to bring together key stakeholders from pharmaceutical, finance and investment, business strategy, as well as governmental science and regulatory segments, according to Conference Chair, Mostafa Analoui, PhD, Head of Healthcare and Life Sciences at Livingston Securities.

“This is an important opportunity to network with significant decision-makers in our industry,” said Dr. Seymour.

NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback